Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus

Nature Communications

Volumn 8, Issue , 2017, Pages

  Pantoja, Petraleigh ^a,b   Pérez Guzmán, Erick X ^b   Rodríguez, Idia V ^a   White, Laura J ^c   González, Olga ^a   Serrano, Crisanta ^b   Giavedoni, Luis ^d   Hodara, Vida ^d   Cruz, Lorna ^a   Arana, Teresa ^b   Martínez, Melween I ^a   Hassert, Mariah A ^e   Brien, James D ^e   Pinto, Amelia K ^e   De Silva, Aravinda ^c   Sariol, Carlos A ^a,b  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; B CELL ACTIVATING FACTOR; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; PERFORIN; ANTISERUM; CYTOKINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY; DISEASE INCIDENCE; IMMUNE RESPONSE; IMMUNITY; INFECTIOUS DISEASE; PATHOGEN; PRIMATE; SERUM; VIRAL DISEASE; VIRUS;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PHENOTYPE; RHESUS MONKEY; SALIVA; URINE; VIRUS IMMUNITY; VIRUS PATHOGENESIS; YOUNG ADULT; ZIKA FEVER; ZIKA VIRUS; ANIMAL; ANIMAL MODEL; ANTIBODY DEPENDENT ENHANCEMENT; DENGUE; DENGUE VIRUS; HUMAN; IMMUNOLOGY; K-562 CELL LINE; PATHOGENICITY;

DENGUE VIRUS; MACACA; MACACA MULATTA; ZIKA VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; CROSS REACTIONS; CYTOKINES; DENGUE; DENGUE VIRUS; HUMANS; IMMUNE SERA; K562 CELLS; MACACA MULATTA; MALE; MODELS, ANIMAL; VIRAL ENVELOPE PROTEINS; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85021355934     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms15674     Document Type: Article

References (59)

1. Faria, N. R. et al. Zika virus in the Americas: early epidemiological and genetic findings. Science 352, 345-349 (2016).
2. Ferguson, N. M. et al. EPIDEMIOLOGY. Countering the Zika epidemic in Latin America. Science 353, 353-354 (2016).
3. WHO. WHO statement on the first meeting of the International Health Regulations (IHR, 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations. http:// www. who. int/mediacentre/news/statements/2016/1st-emergency-committeezika/ en/ (2016).
4. Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48-53 (2016).
5. Green, S. & Rothman, A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr. Opin. Infect. Dis. 19, 429-436 (2006).
6. Screaton, G., Mongkolsapaya, J., Yacoub, S. & Roberts, C. New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol. 15, 745-759 (2015).
7. Guzman, M. G. et al. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev. Panam. Salud Publica 11, 223-227 (2002).
8. Guzman, M. G. & Vazquez, S. The complexity of antibody-dependent enhancement of dengue virus infection. Viruses 2, 2649-2662 (2010).
9. Halstead, S. B. & O'Rourke, E. J. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265, 739-741 (1977).
10. Halstead, S. B. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 140, 527-533 (1979).
11. Sariol, C. A. & White, L. J. Utility, limitations, and future of non-human primates for dengue research and vaccine development. Front. Immunol. 5, 452 (2014).
12. Zompi, S. & Harris, E. Animal models of dengue virus infection. Viruses 4, 62-82 (2012).
13. Fink, J., Gu, F. & Vasudevan, S. G. Role of T cells, cytokines and antibody in dengue fever and dengue haemorrhagic fever. Rev. Med. Virol. 16, 263-275 (2006).
14. Mongkolsapaya, J. et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J. Immunol. 176, 3821-3829 (2006).
15. Bardina, S. V. et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science 356, 175-180 (2017).
16. Dejnirattisai, W. et al. Dengue virus sero-cross-reactivity drives antibodydependent enhancement of infection with zika virus. Nat. Immunol. 17, 1102-1108 (2016).
17. Priyamvada, L. et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc. Natl Acad. Sci. USA 113, 7852-7857 (2016).
18. Cao-Lormeau, V. M. et al. Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387, 1531-1539 (2016).
19. Brasil, P. et al. Zika virus infection in pregnant women in Rio de Janeiro-preliminary report. N. Eng. J. Med 375, 2321-2334 (2016).
20. Cauchemez, S. et al. Association between Zika virus and microcephaly in French Polynesia, 2013-2015: a retrospective study. Lancet 387, 2125-2132 (2016).
21. Butler, D. Brazil asks whether Zika acts alone to cause birth defects. Nature 535, 475-476 (2016).
22. De Goes Cavalcanti, L. P. et al. Zika virus infection, associated microcephaly, and low yellow fever vaccination coverage in Brazil: is there any causal link? J. Infect. Dev. Ctries. 10, 563-566 (2016).
23. Anderson, K. B. et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J. Infect. Dis. 209, 360-368 (2014).
24. Endy, T. P. et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 189, 990-1000 (2004).
25. Montoya, M. et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl. Trop. Dis. 7, e2357 (2013).
26. Osuna, C. E. et al. Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nat. Med. 22, 1448-1455 (2016).
27. Halstead, S. B., Shotwell, H. & Casals, J. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J. Infect. Dis. 128, 15-22 (1973).
28. Halstead, S. B. et al. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J. Infect. Dis. 128, 7-14 (1973).
29. de Alwis, R. et al. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog. 10, e1004386 (2014).
30. Halstead, S. B., Porterfield, J. S. & O'Rourke, E. J. Enhancement of dengue virus infection in monocytes by flavivirus antisera. Am. J. Trop. Med. Hyg. 29, 638-642 (1980).
31. Vaughn, D. W. et al. Dengue in the early febrile phase: viremia and antibody responses. J. Infect. Dis. 176, 322-330 (1997).
32. Best, S. M. The many faces of the flavivirus NS5 protein in antagonism of type i interferon signaling. J. Virol. 91, e01970-16 (2017).
33. Colpitts, T. M. et al. prM-antibody renders immature West Nile virus infectious in vivo. J. Gen. Virol. 92, 2281-2285 (2011).
34. Gould, E. A. & Buckley, A. Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J. Gen. Virol. 70, 1605-1608 (1989).
35. Lanciotti, R. S. et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 14, 1232-1239 (2008).
36. Swanstrom, J. A. et al. Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus. mBio. 7, e01123-16 (2016).
37. Rabe, I. B. et al. Interim guidance for interpretation of zika virus antibody test results. Morb. Mortal. Wkly. Rep. 65, 543-546 (2016).
38. TDR/WHO. Dengue guidelines for diagnosis, treatment, prevention and control WHO/HTM/NTD/DEN/2009. 1 (TDR/WHO, 2009).
39. Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823-826 (2016).
40. Song, H., Qi, J., Haywood, J., Shi, Y. & Gao, G. F. Zika virus NS1 structure reveals diversity of electrostatic surfaces among flaviviruses. Nat. Struct. Mol. Biol. 23, 456-458 (2016).
41. Edeling, M. A., Diamond, M. S. & Fremont, D. H. Structural basis of Flavivirus NS1 assembly and antibody recognition. Proc. Natl Acad. Sci. USA 111, 4285-4290 (2014).
42. Hickey, A. C. et al. Serotype-specific host responses in rhesus macaques after primary dengue challenge. Am. J. Trop. Med. Hyg. 89, 1043-1057 (2013).
43. Gomez, A. M., Ouellet, M. & Tremblay, M. J. HIV-1-triggered release of type I IFN by plasmacytoid dendritic cells induces BAFF production in monocytes. J. Immunol. 194, 2300-2308 (2015).
44. Ittah, M. et al. Induction of B cell-activating factor by viral infection is a general phenomenon, but the types of viruses and mechanisms depend on cell type. J. Innate Immun. 3, 200-207 (2011).
45. Dang, J. et al. Zika virus depletes neural progenitors in human cerebral organoids through activation of the innate immune receptor TLR3. Cell Stem Cell 19, 258-265 (2016).
46. Hamel, R. et al. Biology of Zika virus infection in human skin cells. J. Virol. 89, 8880-8896 (2015).
47. Havenar-Daughton, C. et al. CXCL13 is a plasma biomarker of germinal center activity. Proc. Natl Acad. Sci. USA 113, 2702-2707 (2016).
48. Fazilleau, N., Mark, L., McHeyzer-Williams, L. J. & McHeyzer-Williams, M. G. Follicular helper T cells: lineage and location. Immunity 30, 324-335 (2009).
49. Plourde, A. R. & Bloch, E. M. A literature review of Zika virus. Emerg. Infect. Dis. 22, 1185-1192 (2016).
50. Derrington, S. M. et al. Mucocutaneous findings and course in an adult with Zika virus infection. JAMA Dermatol. 152, 691-693 (2016).
51. Meaney-Delman, D. et al. Prolonged detection of Zika virus RNA in pregnant women. Obstet. Gynecol. 128, 724-730 (2016).
52. Dudley, D. M. et al. A rhesus macaque model of Asian-lineage Zika virus infection. Nat. Commun. 7, 12204 (2016).
53. CDC. Trioplex Real-time RT-PCR Assay. https://www. cdc. gov/zika/pdfs/ trioplex-real-time-rt-pcr-assay-instructions-for-use. pdf (Centers for Disease Control and Prevention, 2016).
54. Johnson, B. W. et al. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am. J. Trop. Med. Hyg. 70, 89-97 (2004).
55. Shi, P. Y. et al. High-throughput detection of West Nile virus RNA. J. Clin. Microbiol. 39, 1264-1271 (2001).
56. Wang, W. K., Lee, C. N., Kao, C. L., Lin, Y. L. & King, C. C. Quantitative competitive reverse transcription-PCR for quantification of dengue virus RNA. J. Clin. Microbiol. 38, 3306-3310 (2000).
57. Meyer, C., Haberthur, K., Asquith, M. & Messaoudi, I. Flow cytometry-based methods to characterize immune senescence in nonhuman primates. Methods Mol. Biol. 1343, 65-80 (2015).
58. Donaldson, M. M. et al. Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies. J. Immunol. Methods 386, 10-21 (2012).
59. Giavedoni, L. D. Simultaneous detection of multiple cytokines and chemokines from nonhuman primates using luminex technology. J. Immunol. Methods 301, 89-101 (2005).